NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Tuesday morning. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Down 4.8 %

NYSE NBY opened at $0.57 on Tuesday. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $10.73. The stock has a market cap of $2.81 million, a price-to-earnings ratio of -0.01 and a beta of 0.69. The company’s 50 day moving average is $0.67 and its two-hundred day moving average is $1.39.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.